Parallax Health Sciences (OTCMKTS:PRLX – Get Free Report) and Illumina (NASDAQ:ILMN – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.
Profitability
This table compares Parallax Health Sciences and Illumina’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Parallax Health Sciences | N/A | N/A | N/A |
| Illumina | 18.36% | 29.84% | 12.17% |
Analyst Recommendations
This is a summary of current ratings and target prices for Parallax Health Sciences and Illumina, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Parallax Health Sciences | 0 | 0 | 0 | 0 | 0.00 |
| Illumina | 2 | 6 | 8 | 1 | 2.47 |
Insider & Institutional Ownership
89.4% of Illumina shares are held by institutional investors. 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Parallax Health Sciences and Illumina”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Parallax Health Sciences | N/A | N/A | N/A | N/A | N/A |
| Illumina | $4.49 billion | 6.41 | $850.00 million | $5.36 | 35.61 |
Illumina has higher revenue and earnings than Parallax Health Sciences.
Summary
Illumina beats Parallax Health Sciences on 9 of the 10 factors compared between the two stocks.
About Parallax Health Sciences
Parallax Health Sciences, Inc. is an integrated digital healthcare company. It is engaged in the provision of personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care diagnostic testing. The firm operates through the following segments: Remote Patient Monitoring, Behavioral Health Systems, and Corporate. The Remote Patient Monitoring segment offers a technology platform that includes a complete remote patient care delivery system through PHM. The Behavioral Health Systems segment includes the intellectual property, Reliable Evidence-Based Outcomes Optimization Technologies, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc. The Corporate segment consists of management and administrative services. The company was founded on July 6, 2005 and is headquartered in Los Angeles, CA.
About Illumina
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
Receive News & Ratings for Parallax Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parallax Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
